News and ViewsIs MiMedx Group, Inc. overvalued or undervalued?
2025-11-23 11:12:08As of 21 November 2025, the valuation grade for MiMedx Group, Inc. moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 24, an EV to EBITDA of 14.64, and a Price to Book Value of 4.75. In comparison to its peers, LeMaitre Vascular, Inc. has a higher P/E of 49.77 and an EV to EBITDA of 33.90, while Alphatec Holdings, Inc. shows a negative P/E, highlighting the variability in valuations within the sector. Despite the fair valuation, MiMedx has underperformed relative to the S&P 500, particularly on a year-to-date basis with a return of -29.73% compared to the index's 12.26%. This underperformance, alongside its current valuation metrics, suggests that while the stock is fairly valued, it may face challenges in regaining momentum in the near term....
Read MoreIs MiMedx Group, Inc. technically bullish or bearish?
2025-11-05 11:23:33As of 31 October 2025, the technical trend for MiMedx Group, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting the bullish stance. However, the daily moving averages remain mildly bearish, which tempers the overall bullish outlook. The RSI shows no signal on the weekly and bearish on the monthly, suggesting caution. In terms of performance, MiMedx has outperformed the S&P 500 over the past week and month, with returns of 14.26% and 6.66% respectively, but it has underperformed on a year-to-date basis with a return of -20.06% compared to the S&P 500's 16.30%. Overall, the current technical stance is mildly bullish, driven by the weekly MACD and Bollinger Bands, despite some bearish indicators on the dail...
Read MoreIs MiMedx Group, Inc. overvalued or undervalued?
2025-11-05 11:11:49As of 31 October 2025, the valuation grade for MiMedx Group, Inc. moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 24, an EV to EBIT of 16.13, and an EV to EBITDA of 14.64, which suggest that while the company is not undervalued, it is also not significantly overvalued compared to its peers. In comparison to its peers, MiMedx's P/E ratio of 33.09 is lower than LeMaitre Vascular, Inc.'s 49.77, indicating a more favorable valuation relative to that competitor, though it is higher than Alphatec Holdings, Inc., which has a negative P/E. Notably, the stock has shown strong performance over the past three years with a return of 164.26%, significantly outperforming the S&P 500's return of 76.66% over the same period. However, the year-to-date return of -20.06% compared to the S&P 500's 16.30%...
Read MoreIs MiMedx Group, Inc. technically bullish or bearish?
2025-11-04 11:35:25As of 31 October 2025, the technical trend for MiMedx Group, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains mildly bearish. The Bollinger Bands are bullish on both the weekly and monthly time frames. Moving averages show a mildly bearish signal on the daily chart, but the Dow Theory supports a mildly bullish outlook on both weekly and monthly charts. In terms of returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 11.74% and 4.30% respectively, while it has underperformed on a year-to-date and one-year basis. Overall, the current technical stance is mildly bullish, driven by the positive signals from the MACD, Bollinger Bands, and Dow Theory....
Read MoreIs MiMedx Group, Inc. technically bullish or bearish?
2025-11-03 11:35:08As of 31 October 2025, the technical trend for MiMedx Group, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are bullish on both weekly and monthly charts, supporting a positive outlook. The Dow Theory also shows a mildly bullish stance on both weekly and monthly periods. However, the daily moving averages are mildly bearish, suggesting caution in the short term. In terms of performance, the stock has returned 13.17% over the past week and 12.01% over the past month, significantly outperforming the S&P 500, which returned 0.71% and 1.92% respectively. However, the year-to-date return of -20.48% lags behind the S&P 500's 16.30%. Overall, the current technical stance is mildly bullish, driven by positive indicators in the weekly timeframe, despite some bearish ...
Read MoreIs MiMedx Group, Inc. overvalued or undervalued?
2025-11-03 11:17:09As of 31 October 2025, the valuation grade for MiMedx Group, Inc. moved from attractive to fair. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 24, an EV to EBIT of 16.13, and an EV to EBITDA of 14.64. In comparison to peers, LeMaitre Vascular, Inc. has a higher P/E ratio of 49.77, while Alphatec Holdings, Inc. shows a negative P/E, indicating it is in a risky position. Despite the fair valuation, MiMedx has shown strong performance in the short term, with a 1-week return of 13.17% compared to the S&P 500's 0.71%, though it has underperformed year-to-date with a return of -20.48% against the S&P 500's 16.30%. Overall, MiMedx Group, Inc. is currently fairly valued within its industry context....
Read MoreIs MiMedx Group, Inc. technically bullish or bearish?
2025-11-02 11:19:16As of 31 October 2025, the technical trend for MiMedx Group, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is mildly bullish, supported by bullish signals from the Bollinger Bands and Dow Theory, while the monthly MACD and KST remain mildly bearish. The daily moving averages indicate a mildly bearish stance. Overall, the current technical stance is mildly bullish, driven by the positive weekly indicators. In terms of returns, MiMedx has outperformed the S&P 500 over the past week and month, with returns of 13.17% and 12.01%, respectively, while it has underperformed on a year-to-date and one-year basis....
Read MoreIs MiMedx Group, Inc. overvalued or undervalued?
2025-11-02 11:10:15As of 31 October 2025, the valuation grade for MiMedx Group, Inc. has moved from attractive to fair. The company appears to be fairly valued given its current P/E ratio of 24, which is lower than the peer average P/E of approximately 33.09, and an EV to EBITDA ratio of 14.64, which is also below the peer average of 18.90. Additionally, the company boasts a strong ROCE of 47.22% and ROE of 19.84%, indicating effective capital utilization and profitability. In comparison to its peers, LeMaitre Vascular, Inc. has a higher P/E of 49.77 and an EV to EBITDA of 33.90, while Stevanato Group SpA is valued attractively with a P/E of 51.03. Despite MiMedx's fair valuation, it has shown strong performance over the past three years with a return of 158.45%, significantly outpacing the S&P 500's return of 76.66% in the same period. However, its year-to-date return of -20.48% trails the S&P 500's 16.30%, suggesting some ...
Read More
MiMedx Group, Inc. Experiences Revision in Stock Score Amid Technical Trend Adjustments
2025-10-14 16:28:31MiMedx Group, Inc. has experienced a technical trend adjustment, indicating bearish sentiment across various indicators. The stock is currently priced at $6.51, reflecting volatility over the past year. While it has struggled year-to-date compared to the S&P 500, it has shown significant returns over a three-year period.
Read More
Announcement
Corporate ActionsCorporate Actions
